Cargando…

Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome

AIMS/INTRODUCTION: Low aerobic capacity is a strong and independent predictor of all‐cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole‐body aerobic capacity and skeletal muscle energy metabolism in MetS patients. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, Takashi, Kinugawa, Shintaro, Hirabayashi, Kagami, Suga, Tadashi, Takada, Shingo, Omokawa, Masashi, Kadoguchi, Tomoyasu, Takahashi, Masashige, Fukushima, Arata, Matsushima, Shouji, Yamato, Mayumi, Okita, Koichi, Tsutsui, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497029/
https://www.ncbi.nlm.nih.gov/pubmed/27930876
http://dx.doi.org/10.1111/jdi.12606
_version_ 1783248087123230720
author Yokota, Takashi
Kinugawa, Shintaro
Hirabayashi, Kagami
Suga, Tadashi
Takada, Shingo
Omokawa, Masashi
Kadoguchi, Tomoyasu
Takahashi, Masashige
Fukushima, Arata
Matsushima, Shouji
Yamato, Mayumi
Okita, Koichi
Tsutsui, Hiroyuki
author_facet Yokota, Takashi
Kinugawa, Shintaro
Hirabayashi, Kagami
Suga, Tadashi
Takada, Shingo
Omokawa, Masashi
Kadoguchi, Tomoyasu
Takahashi, Masashige
Fukushima, Arata
Matsushima, Shouji
Yamato, Mayumi
Okita, Koichi
Tsutsui, Hiroyuki
author_sort Yokota, Takashi
collection PubMed
description AIMS/INTRODUCTION: Low aerobic capacity is a strong and independent predictor of all‐cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole‐body aerobic capacity and skeletal muscle energy metabolism in MetS patients. MATERIALS AND METHODS: A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole‐body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high‐energy phosphates in the calf muscle during plantar‐flexion exercise were measured using (1)proton‐ and (31)phosphorus magnetic resonance spectroscopy, respectively. RESULTS: Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post‐ treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post‐treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high‐energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. CONCLUSIONS: Pioglitazone significantly improved the MetS patients’ whole‐body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole‐body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle.
format Online
Article
Text
id pubmed-5497029
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54970292017-07-14 Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome Yokota, Takashi Kinugawa, Shintaro Hirabayashi, Kagami Suga, Tadashi Takada, Shingo Omokawa, Masashi Kadoguchi, Tomoyasu Takahashi, Masashige Fukushima, Arata Matsushima, Shouji Yamato, Mayumi Okita, Koichi Tsutsui, Hiroyuki J Diabetes Investig Articles AIMS/INTRODUCTION: Low aerobic capacity is a strong and independent predictor of all‐cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole‐body aerobic capacity and skeletal muscle energy metabolism in MetS patients. MATERIALS AND METHODS: A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole‐body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high‐energy phosphates in the calf muscle during plantar‐flexion exercise were measured using (1)proton‐ and (31)phosphorus magnetic resonance spectroscopy, respectively. RESULTS: Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post‐ treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post‐treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high‐energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. CONCLUSIONS: Pioglitazone significantly improved the MetS patients’ whole‐body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole‐body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle. John Wiley and Sons Inc. 2017-01-31 2017-07 /pmc/articles/PMC5497029/ /pubmed/27930876 http://dx.doi.org/10.1111/jdi.12606 Text en © 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Yokota, Takashi
Kinugawa, Shintaro
Hirabayashi, Kagami
Suga, Tadashi
Takada, Shingo
Omokawa, Masashi
Kadoguchi, Tomoyasu
Takahashi, Masashige
Fukushima, Arata
Matsushima, Shouji
Yamato, Mayumi
Okita, Koichi
Tsutsui, Hiroyuki
Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
title Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
title_full Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
title_fullStr Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
title_full_unstemmed Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
title_short Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
title_sort pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497029/
https://www.ncbi.nlm.nih.gov/pubmed/27930876
http://dx.doi.org/10.1111/jdi.12606
work_keys_str_mv AT yokotatakashi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT kinugawashintaro pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT hirabayashikagami pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT sugatadashi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT takadashingo pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT omokawamasashi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT kadoguchitomoyasu pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT takahashimasashige pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT fukushimaarata pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT matsushimashouji pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT yamatomayumi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT okitakoichi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome
AT tsutsuihiroyuki pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome